Main Menu

Company enters key phase

Felstead joins MGB Biopharma board

Steve FelsteadMGB Biopharma, the Glasgow-based clinical stage company developing a novel class of anti-infective drugs, has appointed Steve Felstead to its board.

Since retiring from a senior clinical research position at Pfizer, Dr Felstead has consulted widely on various programmes for pharma/biotech companies and their investors.

Dr Felstead is a member of AdALta Limited’s scientific advisory board and a member of the Scottish borders based angels investment syndicate, TriCap. Earlier this year he was appointed to the role of chief medical officer at Mironid, the Scottish based pharmaceutical company.

Ken Fyvie, chairman of MGB Biopharma, said: “Steve brings a wealth of experience to the MGB Biopharma board and I am confident that he will make a significant contribution to the strategic direction of the business at this exciting time in its development.”

Dr Felstead said: “MGB Biopharma is entering an important phase, with the impending Phase II trial for its lead drug, MGB-BP-3. I am looking forward immensely to being involved in this important next step for the business as this next chapter in its development unfolds.”



Leave a Reply

Your email address will not be published. Required fields are marked as *

This site uses Akismet to reduce spam. Learn how your comment data is processed.